Pharming Group-Aktien behalten Kaufempfehlung nach Zulassung in Großbritannien Von Investing.com

HC Wainwright signed for the open sale and the price of 37.00 US dollars for the Aktien von Pharming Group (NASDAQ: PHAR). Joenja’s war during the British clearing treatment with the active Phosphoinositid-3-Kinase-Delta-Syndroms (APDS) has begun. The Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain has identified Joenja as the first specific therapy for APDS in the country. There is a global presence of Joenja, who is active in the US and Israel.

The British Zulassung ergänzt Pharming Groups laufende regulische Bemühungen in verschiedenen Regionen. The drug is currently available in the EU, Canada and Australia. The Ausschuss für Humanarzneimittel (CHMP) of the European Arzneimittel-Agentur has published an excerpt on the first list of providers, stating that Pharming has an anti-inflammatory drug until January 2026. If you use another device, you must use the device in English to clean the device.

In Canada, the Zulassungszeitplan was launched in 2024, after Pharming received a response from Health Canada in July 2024. Please be aware that the Company is fully informed about the American Depositary Receipts (ADRs) traded at US-Markt.

The MHRA-Zulassung of Joenja has a bedeuten supervisor Meilenstein for Pharming Group dar. If another becomes active, the CHMP investigations in the EU will strengthen their inheritance and power in their recovery activities, a first desired first effort.

The analyst from HC Wainwright carried out his analyzes in the external analyzes during the processing of the Kaufempfehlung and the Kursziels for the ADRs traded by Pharming Groups in the US. The expansion of economic growth in other countries begins on a potential market expansion by joenjas in naher Zukunft hin.

In other cases, the Biopharma-Unternehmen Pharming Group announces a financing and patient recruitment for the main product RUCONEST and Joenja. Der RUCONEST-Umsatz is in a quarter of 23%, while Joenja is a German Umsatzanstieg verzeichnete. The first phase 2 leniolisib study has begun its investigation. The Umsatz forecast for the gesamtjahr yields 280 million and 295 million US dollars, with a value of 35% in a quarter and a stable profit of 89%.

The costs come from investments in Joenja and other managed companies. Sowohl RUCONEST as Joenja says it is a great concern and good patient recruitment. The Unternehmen is probably an indication of Joenja’s troubles with APDS and other indications.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.